Trastuzumab emtansine (T-DM1)

KATHERINE

Trastuzumab emtansine (T-DM1) KATHERINE

PRELIMINARY SCORE

CURATIVE

DFS

Scoring of iDFS on the same basis as DFS

NON-CURATIVE

ADJUSTMENTS

Quality of life

Serious and disabling adverse effects

Other adjustments

Trastuzumab emtansine (T-DM1) KATHERINE

FINAL SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy
Experimental Arm: Trastuzumab emtansine (T-DM1)
Control Arm: Trastuzumab